No Data
SoftBank Group aims to acquire shares from OpenAI employees.
[Generating AI] Softbank Group <9984> is reportedly aiming to increase its investment ratio by acquiring up to $1.5 billion (approximately 230 billion yen) worth of shares from employees of the US OpenAI, as multiple sources have revealed. It is reported that Softbank Group's offer for share acquisition is expected to close within the week. <6702> Fujitsu <7046> TDSE <4011> Headwaters.
Emerging markets stocks digest: Rejil has seen significant continued growth, Agile has made a substantial rebound.
<2158> FRONTEO 604 +4 rebound. The company announced today that it has decided to introduce the audit AI solution 'KIBIT Eye' at Sanwa Securities. 'KIBIT Eye' is an audit AI solution that supports companies' compliance with laws and regulations by analyzing information exchanged in various communication tools such as emails, chats, and phone call transcripts. This introduction will enable Sanwa Securities to
FRONTEO---Resilience, Sanwa Securities decides to introduce audit AI solution "KIBIT Eye"
In a rebound, the company announced today that the auditing AI solution "KIBIT Eye" has been adopted by Sanward Securities. "KIBIT Eye" is an auditing AI solution that supports companies in complying with laws, regulations, and various compliance issues by analyzing information exchanged through various communication tools such as emails, chats, and transcribed call audio data. This adoption will integrate with Sanward Securities' voice transcription system.
FRONTEO - Significant decline, troubled by the performance in the second quarter of the fiscal year ending March 2025.
Significant decline. After the close of trading on the 14th, it was announced that the performance for the second quarter of the fiscal year ending in March 2025 has been released, leading to a sell-off. Revenue was 3.144 billion yen (a decrease of 8.8% compared to the same period last year), operating income was 0.295 billion yen (a shift from an operating loss of 0.492 billion yen in the same period last year), indicating concerns about the decrease in revenue. In addition, UBE and drug repositioning utilizing the company's specialized AI drug discovery support service, "Drug Discovery AI Factory," are mentioned.
Fronteo 1H Net Y206.00M Vs Loss Y511.00M
Fronteo: Summary of financial results for the 2nd quarter (interim period) for the fiscal year ending March 31, 2025 [Japanese GAAP] (Consolidated)
No Data
No Data